Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.855 -3.095 (-1.15%) Market Cap: 34.29 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,063.42 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 10, 2020 / 06:35PM GMT
Release Date Price: $109.39 (-0.52%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Thank you, everyone. My name is Gena Wang. I am mid-cap biotech analyst at the Barclays. I first hope everyone stay healthy, and I would like to thank all the participants, investors, companies and especially our event team and the corporate access team who made this virtual health care conference possible.

With that, I would like to introduce our next speakers from Alnylam, Jeff Poulton, Chief Financial Officer; and also Josh Brodsky, also the leader of the IR team.

I will hand over to you, Josh, maybe for the introduction remarks. I just wanted to remind investors, you have to physically click the slide in order to view the slides, and I'm pretty sure Alnylam team will remind everyone on the page they are on.

Okay. With that, I'll hand over to you, Josh.

Joshua Brodsky
Alnylam Pharmaceuticals, Inc. - Director of IR & Corporate Communications

Terrific. Thanks so much, Gena, and good afternoon, everyone. Again, my name is Josh Brodsky. I'm Director of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot